Spago Nanomedical Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Spago Nanomedical hat ein Gesamteigenkapital von SEK41.1M und eine Gesamtverschuldung von SEK0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen SEK47.1M bzw. SEK6.0M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

SEK 0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	SEK 39.95m
Eigenkapital	SEK 41.12m
Gesamtverbindlichkeiten	SEK 5.98m
Gesamtvermögen	SEK 47.11m

Jüngste Berichte zur Finanzlage

We're Not Worried About Spago Nanomedical's (STO:SPAGO) Cash Burn

Sep 21

We're Interested To See How Spago Nanomedical (STO:SPAGO) Uses Its Cash Hoard To Grow

May 26

We're Hopeful That Spago Nanomedical (NGM:SPAG) Will Use Its Cash Wisely

Feb 03

Recent updates

Most Shareholders Will Probably Agree With Spago Nanomedical AB (publ)'s (STO:SPAGO) CEO Compensation

Jun 04

We're Not Worried About Spago Nanomedical's (STO:SPAGO) Cash Burn

Sep 21

We're Interested To See How Spago Nanomedical (STO:SPAGO) Uses Its Cash Hoard To Grow

May 26

Loss-Making Spago Nanomedical AB (publ) (STO:SPAG) Set To Breakeven

Mar 30

We're Hopeful That Spago Nanomedical (NGM:SPAG) Will Use Its Cash Wisely

Feb 03

Loss-Making Spago Nanomedical AB (publ) (NGM:SPAG) Expected To Breakeven In The Medium-Term

Dec 11

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: SPAGODie kurzfristigen Aktiva des Unternehmens (SEK46.1M) übersteigen seine kurzfristigen Passiva (SEK5.6M).

Langfristige Verbindlichkeiten: SPAGODie kurzfristigen Vermögenswerte des Unternehmens (SEK46.1M) übersteigen seine langfristigen Verbindlichkeiten (SEK405.0K).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: SPAGO ist schuldenfrei.

Schulden abbauen: SPAGO hatte vor 5 Jahren keine Schulden.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: SPAGO auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: SPAGO hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 3.9% pro Jahr abnimmt

Spago Nanomedical Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

We're Not Worried About Spago Nanomedical's (STO:SPAGO) Cash Burn

We're Interested To See How Spago Nanomedical (STO:SPAGO) Uses Its Cash Hoard To Grow

We're Hopeful That Spago Nanomedical (NGM:SPAG) Will Use Its Cash Wisely

Recent updates

Price target decreased by 11% to kr0.80

Third quarter 2024 earnings released

Spago Nanomedical AB (Publ) Appoints Nomination Committee for Annual General Meeting 2025

Consensus revenue estimates increase by 15%

Spago Nanomedical AB (publ)'s Phase I/IIa Study Tumorad-01 Continues Following Successful Treatment Completion of First Patient Group

Second quarter 2024 earnings released

New major risk - Market cap size

New major risk - Financial position

Consensus EPS estimates upgraded to kr0.07 loss

Most Shareholders Will Probably Agree With Spago Nanomedical AB (publ)'s (STO:SPAGO) CEO Compensation

New minor risk - Financial position

Spago Nanomedical AB (publ) to Report Q2, 2024 Results on Aug 21, 2024

Spago Nanomedical AB (publ), Annual General Meeting, Jun 10, 2024

Consensus EPS estimates fall by 15%

Consensus EPS estimates upgraded to kr0.10 loss

Forecast to breakeven in 2026

Spago Nanomedical AB (publ) Reports Favorable Data in Breast Cancer Model with Tumorad

Spago Nanomedical AB (publ) Announces Appointment of Birgitta Rembratt Svensson as Head of CMC & Supply, Effective June 1, 2024

Price target decreased by 35% to kr0.93

Full year 2023 earnings released: kr0.43 loss per share (vs kr0.61 loss in FY 2022)

Spago Nanomedical Proceeds to the Next Dose Level in the Phase I/IIa Study Tumorad-01

New major risk - Shareholder dilution

Spago Nanomedical Announces Positive Top Line Data from a Clinical Phase IIa Study in Patients with Endometriosis

Spago Nanomedical Reports Positive Top Line Data from Clinical Phase IIa Study SPAGOPIX-02 in Patients with Endometriosis

Spago Nanomedical AB (publ) Announces First Patient Dosed in Spago Nanomedical's Clinical Phase I/IIA Study Within the Tumorad(R) Program

Third quarter 2023 earnings released

Spago Nanomedical AB (publ) Announces Publication of Four New Patent Applications Filed with the European Patent Office

Spago Nanomedical Announces Cancer Therapy Approved for Phase I/IIa

Spago Nanomedical AB (publ) Receives Approval to Initiate the Clinical Phase I/IIa Study with Tumorad in Australia

New minor risk - Profitability

No longer forecast to breakeven

Consensus EPS estimates upgraded to kr0.20 loss

Second quarter 2023 earnings released

Spago Nanomedical Updates on the Clinical Phase IIa Study SPAGOPIX-02

Spago Nanomedical AB (Publ) Announces Establishment of A Scientific Advisory Board

High number of new and inexperienced directors

Spago Nanomedical AB (publ) Submits Application to Start Tumorad(R) Clinical Phase I/IIa Study

First quarter 2023 earnings released: kr0.16 loss per share (vs kr0.24 loss in 1Q 2022)

Spago Nanomedical AB (Publ) Elects New Directors

Full year 2022 earnings released: kr0.61 loss per share (vs kr0.99 loss in FY 2021)

Spago Nanomedical AB (Publ) Publishes Scientific Paper on Positive Preclinical Data with Tumorad(R) as Treatment of Solid Tumors

First Patient Dosed in Spago Nanomedical’S Endometriosis Phase Iia Clinical Study

Spago Nanomedical Initiates Clinical Trial with Spagopix in Endometriosis and Concludes SpagoPix -01

Forecast to breakeven in 2023

Price target decreased to kr9.50

Spago Nanomedical Gets SpagoPix Abstract Accepted At Breast Cancer Conference

Spago Nanomedical Announces Process of Entering Clinical Phase with Its Drug Candidate [177]Lu-SN201

Second quarter 2022 earnings released

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast breakeven date pushed back to 2023

Spago Nanomedical AB (publ), Annual General Meeting, May 18, 2022

Forecast breakeven date pushed back to 2023

Full year 2021 earnings: EPS and revenues miss analyst expectations

Spago Nanomedical AB (publ) Announces New Results

Spago Nanomedical Announces Positive Interim Results from Phase I Study with SpagoPix

Spago Nanomedical AB (Publ) Announces Interim Results from the Second Dose Group in Ongoing Clinical Phase I Study SPAGOPIX-01

Spago Nanomedical AB (Publ) Announces That Second Dose Group Fully Recruited in Spago Nanomedical's Phase 1 Study with Spagopix

Third quarter 2021 earnings released

We're Not Worried About Spago Nanomedical's (STO:SPAGO) Cash Burn

Second quarter 2021 earnings released

We're Interested To See How Spago Nanomedical (STO:SPAGO) Uses Its Cash Hoard To Grow

Full year 2020 earnings released: kr0.70 loss per share (vs kr1.01 loss in FY 2019)

Loss-Making Spago Nanomedical AB (publ) (STO:SPAG) Set To Breakeven

Revenue beats expectations, earnings disappoint

Full year 2020 earnings released: kr0.60 loss per share (vs kr1.01 loss in FY 2019)

We're Hopeful That Spago Nanomedical (NGM:SPAG) Will Use Its Cash Wisely

New 90-day high: kr9.14

New 90-day high: kr8.78

Loss-Making Spago Nanomedical AB (publ) (NGM:SPAG) Expected To Breakeven In The Medium-Term

New 90-day high: kr8.08

New 90-day low: kr5.40